- Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX® for previously treated advanced hepatocellular carcinoma - Paris , 04 July.
Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative